Logo image of CATX

PERSPECTIVE THERAPEUTICS INC (CATX) Stock Fundamental Analysis

NYSEARCA:CATX - NYSE Arca - US46489V3024 - Common Stock - Currency: USD

3.17  -0.05 (-1.55%)

After market: 3.16 -0.01 (-0.32%)

Fundamental Rating

2

Overall CATX gets a fundamental rating of 2 out of 10. We evaluated CATX against 557 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. CATX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CATX had negative earnings in the past year.
CATX had a negative operating cash flow in the past year.
CATX had negative earnings in each of the past 5 years.
CATX had a negative operating cash flow in each of the past 5 years.
CATX Yearly Net Income VS EBIT VS OCF VS FCFCATX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -25.86%, CATX is doing good in the industry, outperforming 72.27% of the companies in the same industry.
Looking at the Return On Equity, with a value of -29.92%, CATX is in the better half of the industry, outperforming 78.00% of the companies in the same industry.
Industry RankSector Rank
ROA -25.86%
ROE -29.92%
ROIC N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
CATX Yearly ROA, ROE, ROICCATX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CATX Yearly Profit, Operating, Gross MarginsCATX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has more shares outstanding
The number of shares outstanding for CATX has been increased compared to 5 years ago.
CATX has a better debt/assets ratio than last year.
CATX Yearly Shares OutstandingCATX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CATX Yearly Total Debt VS Total AssetsCATX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.08 indicates that CATX is not a great score, but indicates only limited risk for bankruptcy at the moment.
CATX has a better Altman-Z score (2.08) than 71.02% of its industry peers.
CATX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CATX has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.08
ROIC/WACCN/A
WACC15.92%
CATX Yearly LT Debt VS Equity VS FCFCATX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CATX has a Current Ratio of 17.02. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CATX (17.02) is better than 90.34% of its industry peers.
A Quick Ratio of 17.02 indicates that CATX has no problem at all paying its short term obligations.
CATX has a better Quick ratio (17.02) than 90.52% of its industry peers.
Industry RankSector Rank
Current Ratio 17.02
Quick Ratio 17.02
CATX Yearly Current Assets VS Current LiabilitesCATX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.67% over the past year.
The Revenue for CATX has decreased by -75.62% in the past year. This is quite bad
CATX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.60% yearly.
EPS 1Y (TTM)40.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-75.62%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%5.23%

3.2 Future

CATX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.64% yearly.
CATX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 178.06% yearly.
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-7.64%
Revenue Next Year-50.39%
Revenue Next 2Y-36.56%
Revenue Next 3Y82.38%
Revenue Next 5Y178.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CATX Yearly Revenue VS EstimatesCATX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CATX Yearly EPS VS EstimatesCATX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATX Price Earnings VS Forward Price EarningsCATX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CATX Per share dataCATX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CATX's earnings are expected to decrease with -23.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%

More info and screens

0

5. Dividend

5.1 Amount

CATX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (6/13/2025, 8:04:02 PM)

After market: 3.16 -0.01 (-0.32%)

3.17

-0.05 (-1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)N/A N/A
Inst Owners61.15%
Inst Owner Change-3.68%
Ins Owners3.07%
Ins Owner Change0.1%
Market Cap235.31M
Analysts81.05
Price Target13.57 (328.08%)
Short Float %9.39%
Short Ratio6.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.11%
Min EPS beat(2)7.98%
Max EPS beat(2)20.23%
EPS beat(4)4
Avg EPS beat(4)11.92%
Min EPS beat(4)3.49%
Max EPS beat(4)20.23%
EPS beat(8)6
Avg EPS beat(8)-20.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)63.16%
Min Revenue beat(2)-6.05%
Max Revenue beat(2)132.36%
Revenue beat(4)3
Avg Revenue beat(4)97.07%
Min Revenue beat(4)-6.05%
Max Revenue beat(4)225.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.42%
PT rev (3m)-17.34%
EPS NQ rev (1m)5.36%
EPS NQ rev (3m)4.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.44%
Revenue NQ rev (1m)-10.52%
Revenue NQ rev (3m)-25.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 159.97
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.02
BVpS3.83
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.86%
ROE -29.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1867.23%
Cap/Sales 3404.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.02
Quick Ratio 17.02
Altman-Z 2.08
F-Score4
WACC15.92%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-7.64%
Revenue 1Y (TTM)-75.62%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%5.23%
Revenue Next Year-50.39%
Revenue Next 2Y-36.56%
Revenue Next 3Y82.38%
Revenue Next 5Y178.06%
EBIT growth 1Y0.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.89%
EBIT Next 3Y-20.9%
EBIT Next 5YN/A
FCF growth 1Y-828.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-388.84%
OCF growth 3YN/A
OCF growth 5YN/A